News

Tavapadon eases motor symptoms in early Parkinson’s: Study

Treatment with tavapadon as a fixed-dose single therapy significantly improved motor function in early stage Parkinson’s disease, according to top-line data from a completed Phase 3 trial. Full results from TEMPO-1 (NCT04201093) will be presented at future medical meetings and support regulatory submissions toward the investigational therapy’s approval.

Tiny vesicles from umbilical cord blood may have therapeutic benefit

Administration of tiny cargo-carrying vesicles called exosomes derived from human umbilical cord blood eased motor and cognitive dysfunction in a mouse model of Parkinson’s disease, according to a recent report. The exosomes were able to prevent neurodegeneration, promote nerve cell regeneration, and protect against dysregulated cellular processes implicated…

New mouse model captures disease progression, from gut to brain

A new mouse model replicates the symptoms of Parkinson’s disease and its progression in patients, beginning with diminished smell and other disease nonmotor symptoms that are early signs of the neurodegenerative disorder and often evident before problems with gait and balance arrive, scientists report. Many mouse models overexpress…

Extended-release Parkinson’s therapy Crexont available in US

Crexont, an extended-release formulation of levodopa and carbidopa, is now available in pharmacies across the U.S. for people with Parkinson’s disease. The Parkinson’s therapy, marketed by Amneal Pharmaceuticals  is designed to maintain steady levels of levodopa and carbidopa in the body, extending periods of optimal symptom management,…